Günter Höglinger

Director

Ludwig-Maximilians-Universität München
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

Year:

2026

Background Progressive Supranuclear Palsy (PSP) is a rare and severe neurodegenerative tauopathy characterized by diverse clinical phenotypes, including Richardson's syndrome (PSP‐RS), PSP‐parkinsonism (PSP‐P), PSP‐progressive gait freezing (PSP‐PGF), and PSP‐corticobasal syndrome (PSP‐CBS). Significant geographic variation exists in prevalence, clinical presentations, and prognosis. Objectives This global review aims to systematically evaluate the epidemiological variation, clinical phenotypes, diagnostic practices, and management strategies for PSP, focusing on regional disparities and identifying influencing genetic and environmental factors. Methodology A comprehensive literature search following PRISMA guidelines was conducted, analyzing studies reporting PSP epidemiology, phenotypes, diagnostic criteria, risk factors, treatments, and prognoses. Data were categorized into epidemiology, risk factors, clinical presentations, diagnosis, treatment accessibility, and outcomes, considering geographic variation. Results Global PSP prevalence ranges between 5–6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure. Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction. Prognosis significantly varies with subtype; PSP‐RS shows rapid progression and shorter survival (5–7 years), whereas PSP‐P has a milder clinical course (8–12 years). Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services. Diagnostic accuracy has improved with the adoption of MDS‐PSP criteria, facilitating recognition of diverse phenotypes. Conclusions Regional disparities in PSP prevalence, phenotypic presentation, and healthcare accessibility underscore the importance of standardized diagnostic criteria, targeted genetic and environmental studies, and equitable healthcare strategies. Enhanced global collaboration is essential for improving PSP diagnosis, management, and patient outcomes worldwide.

Year:

2026

Year:

2026

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Cardiovascular autonomic failure is a frequent non-motor feature of Parkinson’s disease (PD) that affects up to one third of individuals from the premotor to the advanced stages of the disease, with major diagnostic, therapeutic and prognostic implications. It may manifest with orthostatic, post-prandial or exercise-induced hypotension, as well as hypertensive episodes in the supine position during wakefulness or nocturnal sleep. Hypotensive episodes may remain asymptomatic or manifest with symptoms of end-organ hypoperfusion in the upright position, after meals or during exertion that may include lightheadedness, blurred vision, cognitive slowness, shuffling gait, back pain, fatigue or, in severe cases, syncope. Supine and nocturnal hypertension are likewise often asymptomatic, yet may cause nocturnal polyuria, and disrupt sleep through frequent nocturnal toilet visits. Bedside screening for cardiovascular autonomic failure relies on targeted history taking, eventually supported by validated questionnaires, and supine to standing heart rate and blood pressure measurements. A more detailed assessment is obtained with cardiovascular autonomic function tests under continuous, non-invasive, hemodynamic monitoring, complemented by 24-hours ambulatory blood pressure monitoring and home blood pressure diaries. Hypotensive episodes are managed by addressing potential triggers, such as infections, anemia, dehydration and polypharmacy, followed by a stepwise implementation of behavioral, non-pharmacological and pharmacological strategies. Individuals with orthostatic hypotension should be constantly monitored for concomitant supine and nocturnal hypertension, especially if treatment with pressor agents has been recently started. Hypertensive episodes are likewise treated in a stepwise fashion with preventive, non-pharmacological and pharmacological measures, prioritizing hypotension control during daytime and mitigating hypertension overnight.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (25)

David J. Pedrosa

-

GERMANY
View details

Wolfgang Jost

head of neurology

Albert-Ludwigs-Universität Freiburg

GERMANY
View details

Georg Kägi

Head of movement disorders center

University Hospital of Bern

SWITZERLAND
View details

Paul Krack

department of basic neuroscience university of geneva geneva switzerland

SWITZERLAND
View details

Stefan Lichtenthaler

Technical University of Munich

GERMANY
View details

Mats Karlsson

Professor

Uppsala University

SWEDEN
View details

Alexander Pantelyat

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Said el Bouhaddani

assistant professor

University Medical Center Groningen

NETHERLANDS
View details

Matthias Brendel

-

GERMANY
View details

Max Wühr

Independent Research Group Leader

Ludwig-Maximilians-Universität München

GERMANY
View details

Karsten Witt

Professor (W3)

Carl von Ossietzky Universität Oldenburg

GERMANY
View details

Praveen Thokala

Reader

University of York

UNITED KINGDOM
View details

Dragomir Milovanovic

University Professor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Martin Posch

Medical University of Vienna

AUSTRIA
View details

Angelo Antonini

Full Professor

University of Padova

ITALY
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Jochen Herms

Full professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Irene Litvan

Professor

University of California, San Diego

UNITED STATES
View details

Anthony E. Lang

-

CANADA
View details

Gabor G. Kovacs

University of Toronto

CANADA
View details

Shijie Ren

University of Sheffield

UNITED KINGDOM
View details

Klaus Jahn

Senior Researcher

Ludwig-Maximilians-Universität München

GERMANY
View details

Björn H. Falkenburger

Academic Staff

Technische Universität Dresden

GERMANY
View details

Piero Parchi

Professore Associato di Neurologia

University of Bologna

ITALY
View details

jean-christophe corvol

Professor of Neurology

Sorbonne Université Campus Pierre et Marie Curie

FRANCE
View details